Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection

Rhea-AI Summary

Medical Care Technologies (OTC:MDCE) has unveiled an innovative AI platform for detecting squamous cell carcinoma (SCC), the second most common form of skin cancer. The technology employs advanced machine learning classifiers to identify early warning signs that might be missed during self-examinations.

The AI system utilizes edge-detection algorithms and keratin pattern recognition to identify various SCC indicators including rough patches, persistent lesions, and early ulcerations. A key feature is its ability to differentiate SCC from precancerous conditions through longitudinal comparison modeling, tracking lesion evolution across the entire body.

Positive

• Development of innovative AI platform for early SCC detection
• Technology capable of detecting warning signs invisible during self-exams
• Advanced features including full-body mapping and longitudinal tracking
• Potential to address a significant health issue affecting thousands annually

Negative

• Early stage technology without proven clinical validation
• No mention of FDA approval status or regulatory timeline
• Lack of information about commercialization strategy or revenue potential

MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant innovation in dermatological AI: a platform capable of detecting squamous cell carcinoma (SCC), the second most common skin cancer and a condition responsible for more than 15,000 deaths annually in the United States alone.

Early SCC detection is critical, as the cancer can spread to lymph nodes and distant organs if untreated. MDCE's AI platform uses advanced machine learning classifiers to spot early warning signs invisible to patients during self-exams.

How the AI Detects SCC

The system applies edge-detection algorithms and keratin pattern recognition to flag:

• Rough, scaly patches or plaques

• Persistent erythematous lesions

• Early ulcerations characteristic of SCC

• Differentiation from precancerous actinic keratosis via longitudinal comparison modeling

By mapping lesions across the entire body and tracking their evolution, the system ensures that high-risk lesions are prioritized for clinical evaluation.

"Our AI doesn't just take snapshots; it builds a timeline of skin health that uncovers hidden dangers before they escalate," said Marshall Perkins, CEO of MDCE. "This technology has the potential to redefine how SCC is caught and treated worldwide."

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC: MDCE) is building a portfolio of AI-powered health solutions spanning dermatology, neurology, and ocular care.

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com

---

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What is Medical Care Technologies' (MDCE) new AI technology for skin cancer?

MDCE has developed an AI platform that uses machine learning to detect squamous cell carcinoma (SCC), the second most common skin cancer. The system uses edge-detection algorithms and keratin pattern recognition to identify early warning signs.

How does MDCE's AI platform detect squamous cell carcinoma?

The AI platform identifies SCC through edge-detection algorithms and keratin pattern recognition, detecting rough patches, persistent lesions, and early ulcerations. It also tracks lesion evolution and differentiates from precancerous conditions.

What are the key features of MDCE's skin cancer detection system?

The system features full-body lesion mapping, longitudinal comparison modeling, and the ability to differentiate between SCC and precancerous actinic keratosis. It can detect warning signs that are typically invisible during self-examinations.

What is the potential impact of MDCE's AI skin cancer detection technology?

The technology could significantly impact SCC detection and treatment worldwide, addressing a condition that causes over 15,000 deaths annually in the US. Early detection is crucial as SCC can spread to lymph nodes and distant organs if untreated.

Who is leading Medical Care Technologies' AI skin cancer initiative?

The initiative is led by Marshall Perkins, CEO of Medical Care Technologies (MDCE), who emphasizes the technology's ability to build a timeline of skin health for early danger detection.